Oct 15th 2012 - Edison Investment Research today published a report on Proteome Sciences (PRM.L, LSE:PRM, LON:PRM) entitled "Tripling Of Sales Still Expected". In summary, the report says:
Proteome Sciences has confirmed it still believes that it will achieve sales of over £3m in FY12. The acceleration in sales growth in H212 will probably be driven by increased demand for its PS Biomarker services; the CHDI Foundation recently entered a collaboration with Proteome Sciences. There is also the prospect of more licensing deals, as a recent paper highlights the utility of its stroke biomarkers and more data is due on its Alzheimer’s disease biomarkers in Q412.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »